Literature DB >> 30506735

Severe hypertension is an independent risk factor for posterior reversible encephalopathy syndrome post-hematopoietic cell transplantation in children with thalassemia major.

Xin-Yu Li1, Ke Huang1, Dun-Hua Zhou1, Yang Li1, Hong-Gui Xu1, Wen-Jun Weng1, Lu-Hong Xu1, Jian-Pei Fang1.   

Abstract

BACKGROUND: Posterior reversible encephalopathy syndrome (PRES) is an increasingly recognized serious complication of cyclosporine A (CSA) and tacrolimus (TAC) use in hematopoietic cell transplantation (HCT) recipients. PROCEDURE: A retrospective study was carried out, including 84 cases of HCT for TM from January 2012 to January 2017. Eleven cases were diagnosed with PRES.
RESULTS: The cumulative incidence of PRES was 13.4% (95% confidence interval (CI) 9.7%-17.2%). The median onset time of the symptoms was 63 [20, 143] days after transplantation. Lumber puncture found that CSF was normal. Univariate analysis showed that patients who received methylprednisolone (MP) (OR = 10.629 95% CI, 1.360-83.071, P = 0.024), female patients (OR = 4.275, 95% CI, 1.154-15.843, P = 0.032), patients who had severe hypertension (OR = 5.162, 95% CI, 1.042 to 25.559, P = 0.029) had significantly higher risks of PRES. Multivariate analysis showed that severe hypertension (hazard ratio [HR], 12.793; 95% CI, 1.477 to 110.813; P  = 0.021), and Pesaro class 3 (HR, 3.367; 95% CI, 1.210 to 9.368; P  =  0.020) were associated with PRES.
CONCLUSIONS: The severe hypertension is an independent risk factor for PRES post-HCT in children with thalassemia major. Patients of Pesaro class 3 may benefit from optimum control of blood pressure post-HCT for prophylaxis of PRES.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  hematopoietic cell transplantation; hypertension; posterior reversible encephalopathy syndrome; thalassemia major

Mesh:

Year:  2018        PMID: 30506735     DOI: 10.1111/ctr.13459

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  2 in total

1.  Neuroimaging findings of posterior reversible encephalopathy syndrome (PRES) following haematopoietic stem cell transplantation in paediatric recipients.

Authors:  Ali Önder Atça; Berrin Erok; Selime Aydoğdu
Journal:  BMC Pediatr       Date:  2021-10-11       Impact factor: 2.125

2.  Management and Clinical Outcome of Posterior Reversible Encephalopathy Syndrome in Pediatric Oncologic/Hematologic Diseases: A PRES Subgroup Analysis With a Large Sample Size.

Authors:  Marady Hun; Min Xie; Zhou She; Amin S Abdirahman; Cuifang Li; Feifeng Wu; Senlin Luo; Phanna Han; Rithea Phorn; Pan Wu; Haiyan Luo; Keke Chen; Jidong Tian; Wuqing Wan; Chuan Wen
Journal:  Front Pediatr       Date:  2021-07-01       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.